Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review-Reference-Cited by-同舟云学术

Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review

Published:2023-02-23 Issue:7 Volume:22 Page:599-609
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Gao Siyuan¹²³,Li Yu⁴,He Zhichao¹²,Zhu Jianhong¹²^ORCID,Liang Dan¹²,Yang Shan¹²,Mo Jiayao⁴,Lam Kakei⁴,Yu Xiaoxia¹²,Huang Ming⁴,Wu Junyan¹²

Affiliation:

1. Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

3. Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, China

4. School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China

Funder

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2181338

Reference48 articles.

1. Cancer and venous thromboembolism

2. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment

3. Drug-Induced Thrombosis: An Update

4. Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors

5. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study;BMC Pharmacology and Toxicology;2024-08-09

2. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS);Expert Opinion on Drug Safety;2024-08-05

3. Spectrum of psychiatric adverse reactions to cyclin‐dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system;CNS Neuroscience & Therapeutics;2024-07

4. CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety;Seminars in Oncology;2023-12